Research Progress of Therapeutic Nanobodies with Different Expression Systems

doi:10.13523/j.cb.2305026

China Biotechnology

2023, Vol. 43

Issue (11): 43-55 DOI: 10.13523/j.cb.2305026

Research Progress of Therapeutic Nanobodies with Different Expression Systems

SUN Bai-he^1,²,WU Yue^1,²,ZHAO Rui³,LOU Yu-xin²,LI Wan-ting²,LI Yan-fei^2,^*(

),MA Lin-lin^2,^*(

)

1 School of Health Science and Engineering,University of Shanghai for Science and Technology,Shanghai 200093,China
2 School of Medical Technology,Shanghai University of Medicine & Health Sciences,Shanghai 201318,China
3 Shanghai Donghai Geriatric Nursing Hospital,Shanghai 201303,China

Download:

HTML

PDF(996KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

The nanobodies existing in the sera of camels and sharks have different structural characteristics and molecular weight from traditional monoclonal antibodies, as well as such characteristics as high specificity, high physicochemical stability and tissue permeability, which show great application potential and are considered to be promising therapeutic proteins in the development of biomedicine. Microorganisms are used to produce expression nanobodies without post-translational modification, which can be produced in large quantities and significantly reduce production costs. At present, the conventional expression systems for producing nanobodies are mainly Escherichia coli, Pichia pastoris, and mammalian cell lines, as well as fungi, plant cells, insect cells and lactobacillus expression systems. E. coli has the advantages of fast growth, high yield, easy culture and cost effectiveness. Pichia pastoris has high expression efficiency, can be cultured in high density, and uses methanol as the only carbon source to reduce pollution. Mammalian cells can adapt to serum-free suspension culture. On this basis, the research progress of characteristics, advantages and applications of different expression systems is reviewed, the urgent problems of each system are analyzed, and the production, research and development of therapeutic nanobody drugs and clinical disease treatment applications are summarized, in order to provide reference for the selection of appropriate expression systems for the production of therapeutic nanobodies and their applications in clinical treatment.

Key words： Nanobody Heterologous expression Antibody drug Expression system Recombinant protein

Received: 16 May 2023 Published: 01 December 2023

ZTFLH:

Q51

Corresponding Authors: *Yan-fei LI,Lin-lin MA E-mail: mall@sumhs.edu.cn;liyf@sumhs.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Bai-he
	WU Yue
	ZHAO Rui
	LOU Yu-xin
	LI Wan-ting
	LI Yan-fei
	MA Lin-lin

Cite this article:

SUN Bai-he, WU Yue, ZHAO Rui, LOU Yu-xin, LI Wan-ting, LI Yan-fei, MA Lin-lin. Research Progress of Therapeutic Nanobodies with Different Expression Systems. China Biotechnology, 2023, 43(11): 43-55.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2305026 OR https://manu60.magtech.com.cn/biotech/Y2023/V43/I11/43

Fig.1 Conventional antibodies and camel heavy chain antibodies

Fig.2 Different systematic nanobody production protocols using phage display libraries

Table 1 Therapeutic nanobodies expressed by E. coli

Table 2 Therapeutic nanobodies expressed by yeast

Table 3 Therapeutic nanobodies expressed by mammalian cell lines and other systems


[1]	Tillib S V. “Camel nanoantibody” is an efficient tool for research, diagnostics and therapy. Molecular Biology, 2011, 45(1): 66-73. doi: 10.1134/S0026893311010134

[2]	Huang L, Gainkam L O T, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Molecular Imaging and Biology, 2008, 10(3): 167-175. doi: 10.1007/s11307-008-0133-8

[3]	Kenanova V, Wu A M. Tailoring antibodies for radionuclide delivery. Expert Opinion on Drug Delivery, 2006, 3(1): 53-70. pmid: 16370940

[4]	Mordenti J. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and fab antibodies in Rhesus monkeys following intravitreal administration. Toxicologic Pathology, 1999, 27(5): 536-544. doi: 10.1177/019262339902700507 pmid: 10528633

[5]	Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects. Nuclear Medicine and Molecular Imaging, 2004, 48(4): 317-325. doi: 10.1007/s13139-014-0294-0

[6]	Vaneycken I, D’huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies. Current Opinion in Biotechnology, 2011, 22(6): 877-881. doi: 10.1016/j.copbio.2011.06.009 pmid: 21726996

[7]	Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature, 1993, 363(6428): 446-448. doi: 10.1038/363446a0

[8]	Muyldermans S. Nanobodies: natural single-domain antibodies. Annual Review of Biochemistry, 2013, 82: 775-797. doi: 10.1146/annurev-biochem-063011-092449 pmid: 23495938

[9]	Bathula N V, Bommadevara H, Hayes J M. Nanobodies: the future of antibody-based immune therapeutics. Cancer Biotherapy & Radiopharmaceuticals, 2021, 36(2): 109-122.

[10]	Farajpour Z, Rahbarizadeh F, Kazemi B, et al. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochemical and Biophysical Research Communications, 2014, 446(1): 132-136. doi: 10.1016/j.bbrc.2014.02.069 pmid: 24569074

[11]	Li T, Bourgeois J P, Celli S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 2012, 26(10): 3969-3979. doi: 10.1096/fsb2.v26.10

[12]	Ren J, Zhang C, Ji F L, et al. Characterization and comparison of two peptide-tag specific nanobodies for immunoaffinity chromatography. Journal of Chromatography A, 2020, 1624: 461227. doi: 10.1016/j.chroma.2020.461227

[13]	Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis and Rheumatism, 2006, 54(6): 1856-1866. pmid: 16736523

[14]	原博, 王杰文, 康广博, 等. 双特异性纳米抗体的研究进展及其应用. 中国生物工程杂志, 2021, 41(S1): 78-88.

[14]	Yuan B, Wang J W, Kang G B, et al. Research progress and application of bispecific nanobody. China Biotechnology, 2021, 41(S1): 78-88.

[15]	van der Linden R H, Frenken L G, de Geus B, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochimica et Biophysica Acta, 1999, 1431(1): 37-46. doi: 10.1016/s0167-4838(99)00030-8 pmid: 10209277

[16]	Rossotti M A, Bélanger K, Henry K A, et al. Immunogenicity and humanization of single-domain antibodies. The FEBS Journal, 2022, 289(14): 4304-4327. doi: 10.1111/febs.v289.14

[17]	Akhila M V, Ken S N, Narwani Tarun J, et al. Discrete analysis of camelid variable domains: sequences, structures, and in-silico structure prediction. PeerJ, 2020, 8: e8408. doi: 10.7717/peerj.8408

[18]	Rathore A, Weiskopf A, Reason A. Defining critical quality attributes for monoclonal antibody therapeutic products. Biopharm International, 2014, 27(7): 34-36, 38.

[19]	Cymer F, Beck H, Rohde A, et al. Therapeutic monoclonal antibody N-glycosylation: structure, function and therapeutic potential. Biologicals, 2018, 52: 1-11. doi: 10.1016/j.biologicals.2017.11.001

[20]	Habib I, Smolarek D, Hattab C, et al. VHH (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. Analytical Biochemistry, 2013, 438(1): 82-89. doi: 10.1016/j.ab.2013.03.020

[21]	Fleetwood F, Devoogdt N, Pellis M, et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cellular and Molecular Life Sciences, 2013, 70(6): 1081-1093. doi: 10.1007/s00018-012-1179-y pmid: 23064703

[22]	Ryckaert S, Pardon E, Steyaert J, et al. Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. Journal of Biotechnology, 2010, 145(2): 93-98. doi: 10.1016/j.jbiotec.2009.10.010 pmid: 19861136

[23]	Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer and Metastasis Reviews, 2005, 24(4): 501-519. doi: 10.1007/s10555-005-6193-1 pmid: 16408159

[24]	Ventola C L. Progress in nanomedicine: approved and investigational nanodrugs. P & T: a Peer-Reviewed Journal for Formulary Management, 2017, 42(12): 742-755.

[25]	Dmitriev O Y, Svetlana L, Serge M. Nanobodies as probes for protein dynamics in vitro and in cells. The Journal of Biological Chemistry, 2016, 291(8): 3767-3775. doi: 10.1074/jbc.R115.679811

[26]	Frenken L G J, van der Linden R H J, Hermans P W J J, et al. Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. Journal of Biotechnology, 2000, 78(1): 11-21. doi: 10.1016/s0168-1656(99)00228-x pmid: 10702907

[27]	Liu Y K, Huang H. Expression of single-domain antibody in different systems. Applied Microbiology and Biotechnology, 2018, 102(2): 539-551. doi: 10.1007/s00253-017-8644-3 pmid: 29177623

[28]	Baeshen M N, Al-Hejin A M, Bora R S, et al. Production of biopharmaceuticals in E. coli: current scenario and future perspectives. Journal of Microbiology and Biotechnology, 2015, 25(7): 953-962. doi: 10.4014/jmb.1412.12079

[29]	Chao S Y, Liu Y H, Ding N, et al. Highly expressed soluble recombinant anti-GFP VHHs in Escherichia coli via optimized signal peptides, strains, and inducers. Frontiers in Molecular Biosciences, 2022, 9: 848829. doi: 10.3389/fmolb.2022.848829

[30]	Bakherad H, Gargari S L M, Rasooli I, et al. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Molecular Biotechnology, 2013, 55(2): 159-167. doi: 10.1007/s12033-013-9669-1 pmid: 23666874

[31]	Shriver-Lake L C, Goldman E R, Zabetakis D, et al. Improved production of single domain antibodies with two disulfide bonds by co-expression of chaperone proteins in the Escherichia coli periplasm. Journal of Immunological Methods, 2017, 443: 64-67. doi: S0022-1759(16)30321-0 pmid: 28131818

[32]	Lao Z T, Li S Q, Liang J H, et al. Production and characterization of GPC3-N protein and its nanobody. Protein Expression and Purification, 2022, 195-196: 106094.

[33]	Manta B, Boyd D, Berkmen M. Disulfide bond formation in the periplasm of Escherichia coli. EcoSal Plus, 2019, 8(2): ESP-0012-2018.

[34]	de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microbial Cell Factories, 2009, 8: 26. doi: 10.1186/1475-2859-8-26 pmid: 19442264

[35]	Cornelis P. Expressing genes in different Escherichia coli compartments. Current Opinion in Biotechnology, 2000, 11(5): 450-454. pmid: 11024362

[36]	Shokri A, Sandén A, Larsson G. Cell and process design for targeting of recombinant protein into the culture medium of Escherichia coli. Applied Microbiology and Biotechnology, 2003, 60(6): 654-664. pmid: 12664143

[37]	Duggan S. Caplacizumab: first global approval. Drugs, 2018, 78(15): 1639-1642. doi: 10.1007/s40265-018-0989-0 pmid: 30298461

[38]	Takeuchi T, Kawanishi M, Nakanishi M, et al. Phase II/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis. Arthritis & Rheumatology, 2022, 74(11): 1776-1785.

[39]	Luo D, Wen C X, Zhao R C, et al. High level expression and purification of recombinant proteins from Escherichia coli with AK-TAG. PLoS One, 2016, 11(5): e0156106. doi: 10.1371/journal.pone.0156106

[40]	Mamat U, Wilke K, Bramhill D, et al. Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microbial Cell Factories, 2015, 14: 57. doi: 10.1186/s12934-015-0241-5 pmid: 25890161

[41]	Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 2011, 118(3): 757-765. doi: 10.1182/blood-2010-11-317859 pmid: 21576702

[42]	Wan R R, Liu A Q, Hou X Q, et al. Screening and antitumor effect of an anti-CTLA-4 nanobody. Oncology Reports, 2018, 39(2): 511-518.

[43]	Papadopoulos K P, Isaacs R, Bilic S, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemotherapy and Pharmacology, 2015, 75(5): 887-895. doi: 10.1007/s00280-015-2712-0 pmid: 25721064

[44]	de Bruin R C G, Veluchamy J P, Lougheed S M, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. Oncoimmunology, 2017, 7(1): e1375641. doi: 10.1080/2162402X.2017.1375641

[45]	Xenaki K T, Dorrestijn B, Muns J A, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics, 2021, 11(11): 5525-5538. doi: 10.7150/thno.57510 pmid: 33859761

[46]	Lennart Z, Annick V, Dominiek C, et al. Selection of non-competitive leptin antagonists using a random nanobody-based approach. The Biochemical Journal, 2012, 441(1): 425-34. doi: 10.1042/BJ20110438

[47]	Kaczmarek J Z, Skottrup P D. Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. Molecular Immunology, 2015, 65(2): 384-390. doi: 10.1016/j.molimm.2015.02.011 pmid: 25749705

[48]	Fan J S, Zhuang X L, Yang X Y, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduction and Targeted Therapy, 2021, 6: 320. doi: 10.1038/s41392-021-00666-5 pmid: 34475375

[49]	Nikkhoi S K, Rahbarizadeh F, Ranjbar S, et al. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting. Molecular Immunology, 2018, 96: 98-109. doi: S0161-5890(18)30017-8 pmid: 29549861

[50]	Ding L, Tian C P, Feng S, et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics, 2015, 5(4): 378-398. doi: 10.7150/thno.10084 pmid: 25699098

[51]	Yang Z Y, Schmidt D, Liu W L, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. The Journal of Infectious Diseases, 2014, 210(6): 964-972. doi: 10.1093/infdis/jiu196

[52]	Steeland S, Puimège L, Vandenbroucke R E, et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. The Journal of Biological Chemistry, 2015, 290(7): 4022-4037. doi: 10.1074/jbc.M114.617787

[53]	Hmila I, Saerens D, Ben Abderrazek R, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. The FASEB Journal, 2010, 24(9): 3479-3489. doi: 10.1096/fsb2.v24.9

[54]	Cristina H, Tremblay Jacqueline M, Shoemaker Charles B, et al. Mechanisms of ricin toxin neutralization revealed through engineered homodimeric and heterodimeric camelid antibodies. The Journal of Biological Chemistry, 2015, 290(46): 27880-27889. doi: 10.1074/jbc.M115.658070

[55]	Yin J C, Li G X, Ren X F, et al. Select what You need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. Journal of Biotechnology, 2007, 127(3): 335-347. pmid: 16959350

[56]	Mattanovich D, Branduardi P, Dato L, et al. Recombinant protein production in yeasts. Methods in Molecular Biology, 2012, 824: 329-358. doi: 10.1007/978-1-61779-433-9_17 pmid: 22160907

[57]	Tyo K E J, Liu Z H, Magnusson Y, et al. Impact of protein uptake and degradation on recombinant protein secretion in yeast. Applied Microbiology and Biotechnology, 2014, 98(16): 7149-7159. doi: 10.1007/s00253-014-5783-7 pmid: 24816620

[58]	Cereghino G P L, Cregg J M. Applications of yeast in biotechnology: protein production and genetic analysis. Current Opinion in Biotechnology, 1999, 10(5): 422-427. pmid: 10508632

[59]	Rachel D, Hearn Milton T W. Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. Journal of Molecular Recognition: JMR, 2005, 18(2): 119-138. doi: 10.1002/(ISSN)1099-1352

[60]	Gerngross T U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nature Biotechnology, 2004, 22(11): 1409-1414. pmid: 15529166

[61]	Roghayyeh B, Mousavi G S L, Masoumeh R, et al. Camelid-derived heavy-chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris. Biotechnology and Applied Biochemistry, 2016, 63(2): 200-205. doi: 10.1002/bab.1226 pmid: 24673401

[62]	Shahrbanoo P, Latif M G S, Masoumeh R, et al. Efficient production of nanobodies against urease activity of Helicobacter pylori in Pichia pastoris. Turkish Journal of Medical Sciences, 2017, 47(2): 695-701. doi: 10.3906/sag-1509-121 pmid: 28425268

[63]	Emberson L M, Trivett A J, Blower P J, et al. Expression of an anti-CD 33 single-chain antibody by Pichia pastoris. Journal of Immunological Methods, 2005, 305(2): 135-151. pmid: 16139294

[64]	Baghban R, Farajnia S, Ghasemi Y, et al. New developments in Pichia pastoris expression system, review and update. Current Pharmaceutical Biotechnology, 2018, 19(6): 451-467. doi: 10.2174/1389201019666180718093037

[65]	van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Research & Therapy, 2015, 17(1): 135.

[66]	Holz J B, Sargentini L, Bruyn S, et al. OP0043 twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody® (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase i/ii study in RA. Annals of the Rheumatic Diseases, 2014, 72: A64-A64. doi: 10.1136/annrheumdis-2013-eular.23

[67]	Detalle L, Stohr T, Palomo C, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobial Agents and Chemotherapy, 2016, 60(1): 6-13. doi: 10.1128/AAC.01802-15 pmid: 26438495

[68]	Ahmad Parray H, Shukla S, Perween R, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Applied Microbiology and Biotechnology, 2021, 105(16): 6315-6332. doi: 10.1007/s00253-021-11488-4

[69]	Liu S, Li G H, Ding L, et al. Evaluation of SARS-CoV-2-neutralizing nanobody using virus receptor binding domain-administered model mice. Research, 2022, 2022: 9864089.

[70]	Wan Y, Gai J, Zhu M, et al. Phase I safety and efficacy evaluation of the first-in-class inhalable anti-IL-4Rα single domain antibody, A33//Late Breaking Advances in Asthma and Immunology. San Francisco :American Thoracic Society, 2023: A1379-A1379.

[71]	Mochizuki S, Hamato N, Hirose M, et al. Expression and characterization of recombinant human antithrombin III in Pichia pastoris. Protein Expression and Purification, 2001, 23(1): 55-65. pmid: 11570846

[72]	Gemmill T R, Trimble R B. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochimica et Biophysica Acta (BBA) - General Subjects, 1999, 1426(2): 227-237. doi: 10.1016/S0304-4165(98)00126-3

[73]	Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochimica et Biophysica Acta (BBA) - General Subjects, 1999, 1426(2): 309-322. doi: 10.1016/S0304-4165(98)00132-9

[74]	Wildt S, Gerngross T U. The humanization of N-glycosylation pathways in yeast. Nature Reviews Microbiology, 2005, 3(2): 119-128. doi: 10.1038/nrmicro1087

[75]	Parsaie Nasab F, Aebi M, Bernhard G, et al. A combined system for engineering glycosylation efficiency and glycan structure in Saccharomyces cerevisiae. Applied and Environmental Microbiology, 2013, 79(3): 997-1007. doi: 10.1128/AEM.02817-12

[76]	Gai J W, Ma L L, Li G H, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm, 2021, 2(1): 101-113. doi: 10.1002/mco2.60 pmid: 33821254

[77]	Roberts K J, Cubitt M F, Carlton T M, et al. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Scientific Reports, 2021, 11: 19422. doi: 10.1038/s41598-021-97236-0 pmid: 34593832

[78]	Terryn S, Francart A, Lamoral S, et al. Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice. PLoS One, 2014, 9(10): e109367. doi: 10.1371/journal.pone.0109367

[79]	Günaydın G, Yu S Z, Gräslund T, et al. Fusion of the mouse IgG 1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus. Scientific Reports, 2016, 6: 30171. doi: 10.1038/srep30171 pmid: 27439689

[80]	Pant N, Marcotte H, Hermans P, et al. Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. Future Microbiology, 2011, 6(5): 583-593. doi: 10.2217/fmb.11.32

[81]	Ji X M, Lu W G, Zhou H T, et al. Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity. Applied Microbiology and Biotechnology, 2013, 97(19): 8547-8558. doi: 10.1007/s00253-012-4639-2

[82]	Ezzine A, M’Hirsi el Adab S, Bouhaouala-Zahar B, et al. Efficient expression of the anti-AahI’ scorpion toxin nanobody under a new functional form in a Pichia pastoris system. Biotechnology and Applied Biochemistry, 2012, 59(1): 15-21. doi: 10.1002/bab.67 pmid: 22332740

[83]	Pan H C, Su Y N, Xie Y N, et al. Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artificial Cells, Nanomedicine, and Biotechnology, 2020, 48(1): 854-866. doi: 10.1080/21691401.2020.1770268

[84]	Hofmeyer T, Bulani S I, Grzeschik J, et al. Protein production in Yarrowia lipolytica via fusion to the secreted lipase Lip2p. Molecular Biotechnology, 2014, 56(1): 79-90. doi: 10.1007/s12033-013-9684-2 pmid: 23852986

[85]	Adams H, Horrevoets W M, Adema S M, et al. Inhibition of biofilm formation by Camelid single-domain antibodies against the flagellum of Pseudomonas aeruginosa. Journal of Biotechnology, 2014, 186: 66-73. doi: 10.1016/j.jbiotec.2014.06.029

[86]	Stolfa G, Smonskey M T, Boniface R, et al. CHO-omics review: the impact of current and emerging technologies on Chinese hamster ovary based bioproduction. Biotechnology Journal, 2018, 13(3): e1700227.

[87]	Swiech K, Picanço-Castro V, Covas D T. Human cells: new platform for recombinant therapeutic protein production. Protein Expression and Purification, 2012, 84(1): 147-153. doi: 10.1016/j.pep.2012.04.023 pmid: 22580292

[88]	Ghaderi D, Zhang M, Hurtado-Ziola N, et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnology & Genetic Engineering Reviews, 2012, 28: 147-175.

[89]	Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Current Opinion in Biotechnology, 2009, 20(6): 700-707. doi: 10.1016/j.copbio.2009.10.008 pmid: 19889531

[90]	Markham A. Envafolimab: first approval. Drugs, 2022, 82(2): 235-240. doi: 10.1007/s40265-022-01671-w pmid: 35122636

[91]	Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Reviews, 2022, 54: 100929. doi: 10.1016/j.blre.2022.100929

[92]	Salvador J P, Vilaplana L, Marco M P. Nanobody: outstanding features for diagnostic and therapeutic applications. Analytical and Bioanalytical Chemistry, 2019, 411(9): 1703-1713. doi: 10.1007/s00216-019-01633-4 pmid: 30734854

[93]	Bobkov V, Zarca A M, Van Hout A, et al. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochemical Pharmacology, 2018, 158: 413-424. doi: S0006-2952(18)30435-0 pmid: 30342023

[94]	Wu X L, Li Y L, Huang B L, et al. A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo. JCI Insight, 2020, 5(13): e136855. doi: 10.1172/jci.insight.136855

[95]	Xun G J, Song X P, Hu J E, et al. Potent human single-domain antibodies specific for a novel prefusion epitope of respiratory syncytial virus F glycoprotein. Journal of Virology, 2021, 95(18): e0048521. doi: 10.1128/JVI.00485-21

[96]	Lu Q Z, Zhang Z L, Li H X, et al. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. Journal of Nanobiotechnology, 2021, 19(1): 33. doi: 10.1186/s12951-021-00768-w pmid: 33514385

[97]	Vandesquille M, Li T F, Po C, et al. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer’s disease. mAbs, 2017, 9(6): 1016-1027. doi: 10.1080/19420862.2017.1342914 pmid: 28657418

[98]	Bao C, Gao Q L, Li L L, et al. The application of nanobody in CAR-T therapy. Biomolecules, 2021, 11(2): 238. doi: 10.3390/biom11020238

[99]	Jiang H P, Ni H Q, Zhang P, et al. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology, 2021, 10(1): 1943180. doi: 10.1080/2162402X.2021.1943180

[100]	Wang Y, Ni H Q, Zhou S X, et al. Tumor-selective blockade of CD 47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunology, Immunotherapy, 2021, 70(2): 365-376. doi: 10.1007/s00262-020-02679-5

[101]	Abe M, Yuki Y, Kurokawa S, et al. A rice-based soluble form of a murine TNF-specific llama variable domain of heavy-chain antibody suppresses collagen-induced arthritis in mice. Journal of Biotechnology, 2014, 175: 45-52. doi: 10.1016/j.jbiotec.2014.02.005 pmid: 24548461

[102]	Pant N, Hultberg A, Zhao Y F, et al. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. The Journal of Infectious Diseases, 2006, 194(11): 1580-1588. doi: 10.1086/jid.2006.194.issue-11

[103]	Mizukami M, Tokunaga H, Onishi H, et al. Highly efficient production of VHH antibody fragments in Brevibacillus choshinensis expression system. Protein Expression and Purification, 2015, 105: 23-32. doi: 10.1016/j.pep.2014.09.017 pmid: 25286401

[104]	Okazaki F, Aoki J I, Tabuchi S, et al. Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment VHH against EGFR. Applied Microbiology and Biotechnology, 2012, 96(1): 81-88. doi: 10.1007/s00253-012-4158-1

[105]	Hisada H, Tsutsumi H, Ishida H, et al. High production of llama variable heavy-chain antibody fragment (VHH) fused to various reader proteins by Aspergillus oryzae. Applied Microbiology and Biotechnology, 2013, 97(2): 761-766. doi: 10.1007/s00253-012-4211-0

[106]	Gomord V, Fitchette A C, Menu-Bouaouiche L, et al. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnology Journal, 2010, 8(5): 564-587. doi: 10.1111/j.1467-7652.2009.00497.x pmid: 20233335

[107]	Tschofen M, Knopp D, Hood E, et al. Plant molecular farming: much more than medicines. Annual Review of Analytical Chemistry (Palo Alto, Calif), 2016, 9(1): 271-294. doi: 10.1146/anchem.2016.9.issue-1

[108]	Łojewska E, Kowalczyk T, Olejniczak S, et al. Extraction and purification methods in downstream processing of plant-based recombinant proteins. Protein Expression and Purification, 2016, 120: 110-117. doi: 10.1016/j.pep.2015.12.018 pmid: 26742898

[109]	Lim C Y, Lee K J, Oh D B, et al. Effect of the developmental stage and tissue position on the expression and glycosylation of recombinant glycoprotein GA733-FcK in transgenic plants. Frontiers in Plant Science, 2014, 5: 778.

[110]	Park S R, Lee J H, Kim K, et al. Expression and in vitro function of anti-breast cancer llama-based single domain antibody VHH expressed in tobacco plants. International Journal of Molecular Sciences, 2020, 21(4): 1354. doi: 10.3390/ijms21041354

[111]	Whaley K J, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Human Vaccines, 2011, 7(3): 349-356. doi: 10.4161/hv.7.3.14266 pmid: 21358287

[112]	Conrad U, Plagmann I, Malchow S, et al. ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnology Journal, 2011, 9(1): 22-31. doi: 10.1111/j.1467-7652.2010.00523.x pmid: 20444206

[113]	Teh Y H A, Kavanagh T A. High-level expression of Camelid nanobodies in Nicotiana benthamiana. Transgenic Research, 2010, 19(4): 575-586. doi: 10.1007/s11248-009-9338-0

[114]	Barrera D J, Rosenberg J N, Chiu J G, et al. Algal chloroplast produced camelid VHH antitoxins are capable of neutralizing botulinum neurotoxin. Plant Biotechnology Journal, 2015, 13(1): 117-124. doi: 10.1111/pbi.12244 pmid: 25229405

[115]	Modarresi M, Javaran M J, Shams-bakhsh M, et al. Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana. 3 Biotech, 2018, 8(12): 484. doi: 10.1007/s13205-018-1500-z pmid: 30467531

[116]	Morello E, Bermúdez-Humarán L G, Llull D, et al. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. Journal of Molecular Microbiology and Biotechnology, 2008, 14(1-3): 48-58. pmid: 17957110

[117]	Andersen K K, Strokappe N M, Hultberg A, et al. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli that produce single-domain antibodies. Infection and Immunity, 2016, 84(2): 395-406. doi: 10.1128/IAI.00870-15 pmid: 26573738

[118]	Cérutti M, Golay J. Lepidopteran cells, an alternative for the production of recombinant antibodies? mAbs, 2012, 4(3): 294-309. doi: 10.4161/mabs.19942 pmid: 22531440

[119]	Gecchele E, Merlin M, Brozzetti A, et al. A comparative analysis of recombinant protein expression in different biofactories: bacteria, insect cells and plant systems. Journal of Visualized Experiments, 2015(97): e52459.

[120]	Contreras-Gómez A, Sánchez-Mirón A, García-Camacho F, et al. Protein production using the baculovirus-insect cell expression system. Biotechnology Progress, 2014, 30(1): 1-18. pmid: 24265112

[121]	Le L T M, Nyengaard J R, Golas M M, et al. Vectors for expression of signal peptide-dependent proteins in baculovirus/insect cell systems and their application to expression and purification of the high-affinity immunoglobulin gamma Fc receptor I in complex with its gamma chain. Molecular Biotechnology, 2018, 60(1): 31-40. doi: 10.1007/s12033-017-0041-8 pmid: 29143175

[122]	Gómez-Sebastián S, Nuñez M C, Garaicoechea L, et al. Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo. BMC Biotechnology, 2012, 12: 59. pmid: 22953695

[123]	Narjes S, Mahdi H, Ali J, et al. Expressing of recombinant VEGFR2-specific nanobody in baculovirus expression system. Iranian Journal of Biotechnology, 2021, 19(1): e2783. doi: 10.30498/IJB.2021.2783 pmid: 34179196

[124]	Magaña-Ortíz D, Fernández F, Loske A M, et al. Extracellular expression in Aspergillus niger of an antibody fused to Leishmania sp. antigens. Current Microbiology, 2018, 75(1): 40-48. doi: 10.1007/s00284-017-1348-1 pmid: 28861662

[125]	Havlik D, Brandt U, Bohle K, et al. Establishment of Neurospora crassa as a host for heterologous protein production using a human antibody fragment as a model product. Microbial Cell Factories, 2017, 16(1): 1-15. doi: 10.1186/s12934-016-0616-2

[126]	Anyaogu D C, Mortensen U H. Manipulating the glycosylation pathway in bacterial and lower eukaryotes for production of therapeutic proteins. Current Opinion in Biotechnology, 2015, 36: 122-128. doi: 10.1016/j.copbio.2015.08.012 pmid: 26340101

[127]	Zubieta M P, Contesini F J, Rubio M V, et al. Protein profile in Aspergillus nidulans recombinant strains overproducing heterologous enzymes. Microbial Biotechnology, 2018, 11(2): 346-358. doi: 10.1111/mbt2.2018.11.issue-2

[1]	MIAO Zhao-yue, DU Le, WANG Jia-qi, CHEN Zi-jie, HUANG Jing-bei, CHEN Qie-xin, ZOU Pei-xuan, HAN Xiao, ZHANG Chun. Soluble Expression Strategies for Production of Recombinant Proteins in Escherichia coli[J]. China Biotechnology, 2023, 43(9): 33-45.

[2]	JIN Mei-qin, SHANG Cheng-zhang, SHEN Yue-lei. Development and Anti-tumor Study of Bispecific Antibody Drug Conjugate Targeting TPBG and EGFR[J]. China Biotechnology, 2023, 43(5): 11-23.

[3]	WANG Mao-jun, SIMAYI Seyide, CAI Yi-an, LI Qing-gang, LU Fu-ping, LI Yu. Effects of Different Signal Peptides and Their Combinations on Heterologous Expression of Levansucrase[J]. China Biotechnology, 2023, 43(5): 37-44.

[4]	WU Yue, SUN Bai-he, ZHAO Rui, LI Yan-fei, MA Lin-lin. Research Progress of Therapeutic Nanobodies with Different Routes of Administration[J]. China Biotechnology, 2023, 43(1): 59-70.

[5]	ZENG Hong-ye,NING Wen-jing,LUO Wen-xin. Advances in the Study of Antibody Composition and Targets of ADC Drugs[J]. China Biotechnology, 2022, 42(5): 69-80.

[6]	WANG Rong-xiang,SONG Jia,SUN Bo,YAN Xue,ZHANG Wan-zhong,ZHAO Chen. Research Progress of Function and Biosynthesis of Coumarins[J]. China Biotechnology, 2022, 42(12): 79-90.

[7]	Qiong WU,Xin ZHAO,Yu-yao DU,Shu-hong MAO. Co-expression and Functional Analysis of Cytochrome P450 Reductase and CYP17[J]. China Biotechnology, 2022, 42(10): 1-8.

[8]	LI Ding,LI Lan,AN Yun-fei,BI Zhen-wei,YU Xiao-ming,CHEN Jin,ZHENG Qi-sheng. Optimized Yeast Expression of Canine Interferon-α Using a Combined Strategy[J]. China Biotechnology, 2022, 42(1/2): 88-95.

[9]	LI Bing,ZHANG Chuan-bo,SONG Kai,LU Wen-yu. Research Progress in Biosynthesis of Rare Ginsenosides[J]. China Biotechnology, 2021, 41(6): 71-88.

[10]	WANG Hui-lin,ZHOU Kai-qiang,ZHU Hong-yu,WANG Li-jing,YANG Zhong-fan,XU Ming-bo,CAO Rong-yue. Research Progress of Human Coagulation Factor VII and the Recombinant Expression Systems[J]. China Biotechnology, 2021, 41(2/3): 129-137.

[11]	YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.

[12]	RAO Hai-mi,LIANG Dong-mei,LI Wei-guo,QIAO Jian-jun,CAI YIN Qing-ge-le. Advances in Synthetic Biology of Fungal Aromatic Polyketides[J]. China Biotechnology, 2020, 40(9): 52-61.

[13]	LIN Shi-xin,LIU Dong-chen,LEI Yun,XIONG Sheng,XIE Qiu-ling. Screening, Expression and Specificity Detection of Anti-TNF-α Nanobody[J]. China Biotechnology, 2020, 40(7): 15-21.

[14]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[15]	WEI Wei,CHANG Bao-gen,WANG Ying,LU Fu-ping,LIU Fu-feng. Heterologous Expression, Purification and Aggregation Characterization of Tau Core Fragment 306-378[J]. China Biotechnology, 2020, 40(5): 22-29.

Viewed

Full text

Abstract

Cited

Shared

Discussed